SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 1331-1333. Prepublished online as a Blood First Edition Paper on October 5, 2006; DOI 10.1182/blood-2006-04-018606. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-018606v1 109/3/1331    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Peranteau, W. H Articles by Flake, A. W. Search for Related Content PubMed PubMed Citation Articles by Peranteau, W. H Articles by Flake, A. W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 24, 2006 Accepted August 12, 2006 Evidence for an Immune Barrier after In Utero Hematopoietic Cell Transplantation William H Peranteau, Masayuki Endo, Obinna O Adibe, and Alan W. Flake* The Center for Fetal Research, The Children's Hospital of Philadelphia, PA * Corresponding author; email: flake{at}email.chop.edu. The competence of the immune system of the developing fetus to act as a barrier to in utero hematopoietic cell transplantation (IUHCT) has been a source of debate. Until now, comparisons of allogeneic and congenic engraftment have been inconclusive due to methodologic limitations resulting in minimal and inefficient engraftment. In this study, we transplanted E14 fetal mice with either allogeneic or congenic BM using a new intravascular technique that allows definitive administration of much higher doses of donor cells. Our results demonstrate that 100% of surviving recipients demonstrate engraftment at 1 week of age, but that 70% of allogeneic recipients lose engraftment by 1 month of age, and 80% ultimately fail to sustain long-term chimerism. In contrast, all congenic recipients maintain stable, long-term, multilineage chimerism. These results strongly support an immune barrier to allogeneic engraftment after IUHCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Liuba, C. J. H. Pronk, S. R. W. Stott, and S.-E. W. Jacobsen Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors Blood, May 7, 2009; 113(19): 4790 - 4798. [Abstract] [Full Text] [PDF] C.-P. Chen, S.-H. Liu, J.-P. Huang, J. D. Aplin, Y.-H. Wu, P.-C. Chen, C.-S. Hu, C.-C. Ko, M.-Y. Lee, and C.-Y. Chen Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats Hum. Reprod., January 1, 2009; 24(1): 154 - 165. [Abstract] [Full Text] [PDF] T. Chino, K. Tamai, T. Yamazaki, S. Otsuru, Y. Kikuchi, K. Nimura, M. Endo, M. Nagai, J. Uitto, Y. Kitajima, et al. Bone Marrow Cell Transfer into Fetal Circulation Can Ameliorate Genetic Skin Diseases by Providing Fibroblasts to the Skin and Inducing Immune Tolerance Am. J. Pathol., September 1, 2008; 173(3): 803 - 814. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020